BEDFORD, Mass., Jan. 31, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is pleased to announce the appointment of Mark D. Myslinski as Senior Vice President and General Manager, Diagnostics. Mr. Myslinski will oversee the Company's Diagnostics Group including all cytology and molecular diagnostics products.
Mr. Myslinski brings to Hologic 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed start up organizations. Most recently, he served as President and Chief Executive Officer for RedPath Integrated Pathology, Inc., a genomics-based cancer diagnostic company. Prior to RedPath, Mr. Myslinski held positions as Vice President and a member of the Board of Ortho Clinical Diagnostics, Inc., a division of Johnson & Johnson, and Veridex, LLC, where he was the Vice President and General Manager.
"We are pleased to have Mark join the Hologic senior management team," said Rob Cascella, Hologic's CEO. "His extensive operating experience in the rapidly changing clinical diagnostics market will be a most valuable addition to the Company. Mark will lead the growth initiatives of our Diagnostics franchise and reshape the strategic priorities of this extremely important business unit."
Mr. Myslinski earned his M.B.A. from Ohio University and his B.A. from Moravian College. In June of 2010, he was appointed to the Board of Directors of OncoMethylome Sciences SA, now known as MDxHealth, SA, a molecular diagnostics company that commercializes and develops cancer tests to assist physicians in personalizing cancer treatment.
About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium di